{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T04:37:14Z","timestamp":1794803834577,"version":"4.9.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Child Psychiatry Hum Dev"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Angelman syndrome (AS) is a complex, heterogeneous, and life-long neurodevelopmental disorder. Despite the considerable impact on individuals and caregivers, no disease-modifying treatments are available. To support holistic clinical management and the development of AS-specific outcome measures for clinical studies, we conducted primary and secondary research identifying the impact of symptoms on individuals with AS and their unmet need. This qualitative research adopted a rigorous step-wise approach, aggregating information from published literature, then evaluating it via disease concept elicitation interviews with clinical experts and caregivers. We found that the AS-defining concepts most relevant for treatment included: impaired expressive communication, seizures, maladaptive behavior, cognitive impairment, motor function difficulties, sleep disturbance, and limited self-care abilities. We highlight the relevance of age in experiencing these key AS concepts, and the difference between the perceptions of clinicians and caregivers towards the syndrome. Finally, we outline the impact of AS on individuals, caregivers, and families.<\/jats:p>","DOI":"10.1007\/s10578-020-01051-z","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T16:02:32Z","timestamp":1599062552000},"page":"654-668","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Measuring What Matters to Individuals with Angelman Syndrome and Their Families: Development of a Patient-Centered Disease Concept Model"],"prefix":"10.1007","volume":"52","author":[{"given":"Tom","family":"Willgoss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiana","family":"Cassater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan","family":"Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan T.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Dias-Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne M.","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca D.","family":"Burdine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Claridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry Jo","family":"Bichell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,2]]},"reference":[{"key":"1051_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13052-016-0301-4","volume":"42","author":"S Micheletti","year":"2016","unstructured":"Micheletti S, Palestra F, Martelli P, Accorsi P, Galli J, Giordano L et al (2016) Neurodevelopmental profile in Angelman syndrome: more than low intelligence quotient. Ital J Pediatr 42:91","journal-title":"Ital J Pediatr"},{"key":"1051_CR2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000328837","volume":"2","author":"A Dagli","year":"2012","unstructured":"Dagli A, Buiting K, Williams CA (2012) Molecular and clinical aspects of angelman syndrome. Mol Syndromol 2:100\u2013112","journal-title":"Mol Syndromol"},{"key":"1051_CR3","doi-asserted-by":"crossref","unstructured":"Kyllerman M (1995) On the prevalence of Angelman syndrome. Am J Med Genet 59: 405; author reply 403\u2013404.","DOI":"10.1002\/ajmg.1320590330"},{"key":"1051_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/ajmg.1320600317","volume":"60","author":"MB Petersen","year":"1995","unstructured":"Petersen MB, Brondum-Nielsen K, Hansen LK, Wulff K (1995) Clinical, cytogenetic, and molecular diagnosis of Angelman syndrome: estimated prevalence rate in a Danish county. Am J Med Genet 60:261\u2013262","journal-title":"Am J Med Genet"},{"key":"1051_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/(SICI)1096-8628(19981204)80:4<385::AID-AJMG15>3.0.CO;2-9","volume":"80","author":"RH Buckley","year":"1998","unstructured":"Buckley RH, Dinno N, Weber P (1998) Angelman syndrome: are the estimates too low? Am J Med Genet 80:385\u2013390","journal-title":"Am J Med Genet"},{"key":"1051_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/GIM.0b013e3181def138","volume":"12","author":"CA Williams","year":"2010","unstructured":"Williams CA, Driscoll DJ, Dagli AI (2010) Clinical and genetic aspects of Angelman syndrome. Genet Med 12:385\u2013395","journal-title":"Genet Med"},{"key":"1051_CR7","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1365-2788.2011.01386.x","volume":"55","author":"GM Griffith","year":"2011","unstructured":"Griffith GM, Hastings RP, Oliver C, Howlin P, Moss J, Petty J et al (2011) Psychological well-being in parents of children with Angelman, Cornelia de Lange and Cri du Chat syndromes. J Intellect Disabil Res 55:397\u2013410","journal-title":"J Intellect Disabil Res"},{"key":"1051_CR8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/ajmg.a.31074","volume":"140","author":"CA Williams","year":"2006","unstructured":"Williams CA, Beaudet AL, Clayton-Smith J, Knoll JH, Kyllerman M, Laan LA et al (2006) Angelman syndrome 2005: updated consensus for diagnostic criteria. Am J Med Genet A 140:413\u2013418","journal-title":"Am J Med Genet A"},{"key":"1051_CR9","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/ajmg.c.31536","volume":"172","author":"WH Tan","year":"2016","unstructured":"Tan WH, Bird LM (2016) Angelman syndrome: current and emerging therapies in 2016. Am J Med Genet C 172:384\u2013401","journal-title":"Am J Med Genet C"},{"key":"1051_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13023-017-0618-0","volume":"12","author":"S Dharssi","year":"2017","unstructured":"Dharssi S, Wong-Rieger D, Harold M, Terry S (2017) Review of 11 national policies for rare diseases in the context of key patient needs. Orphanet J Rare Dis 12:63","journal-title":"Orphanet J Rare Dis"},{"key":"1051_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s10897-018-0294-9","volume":"28","author":"J Baumbusch","year":"2018","unstructured":"Baumbusch J, Mayer S, Sloan-Yip I (2018) Alone in a crowd? Parents of children with rare diseases' experiences of navigating the healthcare system. J Genet Couns 28:80\u201390","journal-title":"J Genet Couns"},{"key":"1051_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13023-017-0716-z","volume":"12","author":"AC Wheeler","year":"2017","unstructured":"Wheeler AC, Sacco P, Cabo R (2017) Unmet clinical needs and burden in Angelman syndrome: a review of the literature. Orphanet J Rare Dis 12:164","journal-title":"Orphanet J Rare Dis"},{"key":"1051_CR13","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S1474-4422(19)30357-6","volume":"18","author":"The Lancet Neurology","year":"2019","unstructured":"The Lancet Neurology (2019) Patient-reported outcomes in the spotlight. Lancet Neurol 18:981","journal-title":"Lancet Neurol"},{"key":"1051_CR14","first-page":"79","volume":"4","author":"US Department of Health and Human Services FDA Center for Drug Evaluation and Research, US Department of Health and Human Services FDA Center for Biologics Evaluation and Research, US Department of Health and Human Services FDA Center for Devices and Radiological Health","year":"2009","unstructured":"US Department of Health and Human Services FDA Center for Drug Evaluation and Research, US Department of Health and Human Services FDA Center for Biologics Evaluation and Research, US Department of Health and Human Services FDA Center for Devices and Radiological Health (2009) Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 4:79","journal-title":"Health Qual Life Outcomes"},{"key":"1051_CR15","unstructured":"Alliance ABaOM. https:\/\/www.angelmanbiomarkers.org. Accessed 11 March 2020."},{"key":"1051_CR16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2165\/00019053-200826050-00002","volume":"26","author":"NK Leidy","year":"2008","unstructured":"Leidy NK, Vernon M (2008) Perspectives on patient-reported outcomes: content validity and qualitative research in a changing clinical trial environment. Pharmacoeconomics 26:363\u2013370","journal-title":"Pharmacoeconomics"},{"key":"1051_CR17","doi-asserted-by":"publisher","first-page":"PA386","DOI":"10.1016\/j.jval.2016.09.225","volume":"19","author":"L Abetz-Webb","year":"2016","unstructured":"Abetz-Webb L, Cabo R, Grieco J, Rakhit A, During M (2016) Conceptual model and clinical outcomes assessments for Angelman\u2019s syndrome: utilizing pragmatic methods in rare diseases. Value Health 19:PA386","journal-title":"Value Health"},{"key":"1051_CR18","doi-asserted-by":"publisher","first-page":"O14","DOI":"10.1186\/1750-1172-5-S1-O14","volume":"5","author":"K Chrzanowska","year":"2010","unstructured":"Chrzanowska K, Clayton-Smith J, Day R, Griffiths P (2010) DYSCERNE: a European Network of Centres of Expertise for Dysmorphology. Orphanet J Rare Dis 5:O14","journal-title":"Orphanet J Rare Dis"},{"key":"1051_CR19","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrneurol.2016.133","volume":"12","author":"K Buiting","year":"2016","unstructured":"Buiting K, Williams C, Horsthemke B (2016) Angelman syndrome\u2014insights into a rare neurogenetic disorder. Nat Rev Neurol 12:584\u2013593","journal-title":"Nat Rev Neurol"},{"key":"1051_CR20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/ajmg.a.36864","volume":"167A","author":"AM Larson","year":"2015","unstructured":"Larson AM, Shinnick JE, Shaaya EA, Thiele EA, Thibert RL (2015) Angelman syndrome in adulthood. Am J Med Genet A 167A:331\u2013344","journal-title":"Am J Med Genet A"},{"key":"1051_CR21","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1002\/ajmg.a.37254","volume":"167A","author":"LK Wink","year":"2015","unstructured":"Wink LK, Fitzpatrick S, Shaffer R, Melnyk S, Begtrup AH, Fox E et al (2015) The neurobehavioral and molecular phenotype of Angelman Syndrome. Am J Med Genet A 167A:2623\u20132628","journal-title":"Am J Med Genet A"},{"key":"1051_CR22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/ca.22659","volume":"29","author":"R Sachdeva","year":"2016","unstructured":"Sachdeva R, Donkers SJ, Kim SY (2016) Angelman syndrome: a review highlighting musculoskeletal and anatomical aberrations. Clin Anat 29:561\u2013567","journal-title":"Clin Anat"},{"key":"1051_CR23","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3109\/09638288.2016.1161838","volume":"39","author":"A Thomson","year":"2017","unstructured":"Thomson A, Glasson E, Roberts P, Bittles A (2017) \"Over time it just becomes easier..\": parents of people with Angelman syndrome and Prader-Willi syndrome speak about their carer role. Disabil Rehabil 39:763\u2013770","journal-title":"Disabil Rehabil"},{"key":"1051_CR24","unstructured":"Wolrd Health Organisation (2018) International Classification of Functioning, Disability and Health (ICF) https:\/\/www.who.int\/classifications\/icf\/en\/.Accessed 11 March 2020."},{"key":"1051_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1586\/erp.10.30","volume":"10","author":"C Kerr","year":"2014","unstructured":"Kerr C, Nixon A, Wild D (2014) Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research. Expert Rev Pharmacoecon Outcomes Res 10:269\u2013281","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1051_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s13023-019-1210-6","volume":"14","author":"N Khan","year":"2019","unstructured":"Khan N, Cabo R, Tan WH, Tayag R, Bird LM (2019) An observational study of pediatric healthcare burden in Angelman syndrome: results from a real-world study. Orphanet J Rare Dis 14:239","journal-title":"Orphanet J Rare Dis"},{"key":"1051_CR27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13023-019-1134-1","volume":"14","author":"B Gomez-Zuniga","year":"2019","unstructured":"Gomez-Zuniga B, Pulido Moyano R, Pousada Fernandez M, Garcia Oliva A, Armayones RM (2019) The experience of parents of children with rare diseases when communicating with healthcare professionals: towards an integrative theory of trust. Orphanet J Rare Dis 14:159","journal-title":"Orphanet J Rare Dis"},{"key":"1051_CR28","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/ajmg.a.38629","volume":"176","author":"GF Cox","year":"2018","unstructured":"Cox GF (2018) The art and science of choosing efficacy endpoints for rare disease clinical trials. Am J Med Genet A 176:759\u2013772","journal-title":"Am J Med Genet A"},{"key":"1051_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40271-018-0323-7","volume":"12","author":"JC Grieco","year":"2019","unstructured":"Grieco JC, Romero B, Flood E, Cabo R, Visootsak J (2019) A conceptual model of Angelman syndrome and review of relevant clinical outcomes assessments (COAs). Patient 12:97\u2013112","journal-title":"Patient"},{"key":"1051_CR30","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1002\/ajmg.a.38401","volume":"173","author":"LW Glassman","year":"2017","unstructured":"Glassman LW, Grocott OR, Kunz PA, Larson AM, Zella G, Ganguli K et al (2017) Prevalence of gastrointestinal symptoms in Angelman syndrome. Am J Med Genet A 173:2703\u20132709","journal-title":"Am J Med Genet A"}],"container-title":["Child Psychiatry &amp; Human Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10578-020-01051-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10578-020-01051-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10578-020-01051-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T22:14:15Z","timestamp":1668550455000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10578-020-01051-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,2]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1051"],"URL":"https:\/\/doi.org\/10.1007\/s10578-020-01051-z","relation":{},"ISSN":["0009-398X","1573-3327"],"issn-type":[{"value":"0009-398X","type":"print"},{"value":"1573-3327","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,2]]},"assertion":[{"value":"2 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Tom Willgoss and Siobhan Connor are employees and shareholders of Roche. Daiana Cassater is an employee of Roche. Michelle L. Krishnan and Meghan T. Miller were employees of Roche at the time of writing. Dawn Phillips and Sharon Claridge declared no conflicts of interest. Carla Dias Barbosa and Julie McCormack are employees of Evidera, which provides consulting and other research services to pharmaceutical, device, government, and non-government organizations. As Evidera employees, they work with a variety of companies and organizations and are expressly prohibited from receiving any personal payment or honoraria directly from these organizations for services rendered. Lynne M. Bird has received research support from Ovid Therapeutics, Inc. to conduct clinical trials, research support from F. Hoffman-La Roche to provide data from the Angelman syndrome natural history study, research support from F. Hoffman-La Roche\/Genentech to conduct clinical trials, research support from FDA (via subcontract through Boston Children\u2019s Hospital) to conduct natural history study, and honoraria support from Ionis Pharmaceuticals to participate in Scientific Advisory Board. Rebecca Burdine is a clinical trial steering committee member for Ovid Therapeutics, and a Board and SAB member of Angelman Syndrome Foundation. Terry Jo Bichell contributes to the Consortium for Outcome Measures and Biomarkers for Neurodevelopmental Disorders, Nashville TN.\n                      \n                      , including a former affiliation with Angelman Biomarkers and Outcome Measures Alliance.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For the interviews performed, all procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1964, as revised in 2013. Ethical approval was obtained from the relevant IRBs in each country (ethics approval codes: study number 18000-01 and MEC-2018-084).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Written consent was obtained from participants. Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}